medigraphic.com
ISSN 1027-2852 (Electronic)
ISSN 0864-4551 (Print)

2019, Number 3

<< Back Next >>

Biotecnol Apl 2019; 36 (3)

Pharmacogenomic study of EGF treatment in a rat DSS-induced colitis animal model

Roca J, Camacho H, Guillén IA, Aguilera A, Bermudez Y, Palenzuela DO, Novoa LI

Language: English
References: 30
Page: 3211-3215
PDF size: 336.49 Kb.


ABSTRACT

Ulcerative colitis (UC) is a human chronic inflammatory disease of the colon and rectum, of partially characterized etiology. The Dextran Sulfate Sodium-induced colitis model in rats molecularly reproduces the human disease, aiding to evaluate therapeutic formulations aimed to repair the damage at the intestinal mucosa. Previous experiments have shown the effectiveness of rhEGF for healing colitis. However, the changes in the gene expression profile associated to that positive effect and its mechanism of action have been poorly studied. Therefore, this work was aimed to evaluate the colitis-related gene expression in the DSS model in rats, seven days after treatment with rhEGF formulated in pellet. Samples of distal colon tissue were taken from rats with DSS-induced colitis treated with rhEGF, followed by the extraction of total RNA. The gene expression of 46 genes was analyzed by quantitative PCR, those genes related to inflammation, oxidative stress, and cell differentiation and proliferation processes. The oral treatment with the rhEGF pellet formulation was shown effective, with more than 50 % of the analyzed genes related to inflammation and oxidative stress showing a statistically-significant decrease in their expression (p = 0.05). Moreover, a reverted expression profile was found for the genes involved in cell differentiation and proliferation processes in comparison with untreated animals. All this suggested the positive effect of the treatment with rhEGF formulated in pellet on the restoration of the intestinal epithelium, with the subsequent decrease in inflammation and oxidative stress.


REFERENCES

  1. M’Koma AE. Inflammatory bowel disease: An expanding global health problem. Clin Med Insights Gastroenterol. 2013;l6:33-47.

  2. Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc. 2014;89(11):1553-63.

  3. Katsanos KH, Papadakis KA. Inflammatory bowel disease: Updates on molecular targets for biologics. Gut Liver. 2017;11(4):455-63.

  4. Rana SV, Sharma S, Kaur J, Prasad KK, Sinha SK, Kochhar R, et al. Relationship of cytokines, oxidative stress and GI motility with bacterial overgrowth in ulcerative colitis patients. J Crohn’s Colitis. 2014;8:859-65.

  5. Bhattacharyya A, Chattopadhyay R, Mitra S, Crowe SE. Oxidative stress: an essential factor in the pathogenesis of gastrointestinal mucosal diseases. Physiol Rev. 2014;94:329-54.

  6. Okamoto R, Watanabe M. Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease. J Gastroenterol. 2016;51(1):11-21.

  7. Bloemendaal ALA, Buchs NC, George BD, Guy RJ. Intestinal stem cells and intestinal homeostasis in health and in inflammation: A review. Surgery. 2016;159:1237-48.

  8. Van der Flier LG, Clevers H. Stem cells, self-renewal, and differentiation in the intestinal epithelium. Annu Rev Physiol. 2009;71:241-60.

  9. Qi Z, Chen YG. Regulation of intestinal stem cell fate specification. Sci China Life Sci. 2015;58:570-8.

  10. Atul Sinha A, Nightingale J, West KP, Berlanga J, Playford RJ. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. Engl J Med. 2003;349:350-7.

  11. Elliott SN, Wallace JL, Mcknight W, Gall DG, Hardin JA, Olson M, et al. Bacterial colonization and healing of gastric ulcers: the effects of epidermal growth factor. Am J Physiol Gastrointest Liver Physiol. 2000;278(1):G105-12.

  12. Kuwahara Y, Sunagawa Y, Imoto Y, Okabe S. Effects of orally administered human epidermal growth factor on natural and delayed healing of acetic acid-induced gastric ulcers in rats. Japan J Pharmacol. 1990;52(1):164-6.

  13. Roca J, Camacho H, Guillen IA, Aguilera A, Palenzuela DO, Silva JA, et al. Pharmacogenomic assessment of an acute colitis model. Bionatura. 2018;3(2):577-81.

  14. Ubieta-Gómez R, Aguilera-Barreto A, Martínez-Díaz E, Páez-Meireles R, Sereno- Guerra A, inventors; Centro de Ingeniería Genética y Biotecnología (CIGB), BIOREC SA, assignees. Orally administrable pharmaceutical pellet of epidermal growth factor. European Patent 2533758B1. 2015 Apr 08.

  15. Solomon L, Mansor S, Mallon P, Donnelly E, Hoper M, Loughrey M, et al. The dextran sulphate sodium (DSS) model of colitis: an overview. Comp Clin Pathol. 2010;19:235-9.

  16. CIGB. Programa para el Uso y Manejo del Animal de Laboratorio con fines Experimentales y para el Control de Productos Biotecnológicos del Centro de Ingeniería Genética y Biotecnología de la Habana, Cuba. La Habana: CIGB; 2016.

  17. FitzGerald AJ, Puc M, Marchbank T, Westley BR, Mayc FEB, Boyle J, et al. Synergistic effects of systemic trefoil factor family 1 (TFF1) peptide and epidermal growth factor in a rat model of colitis. Peptides. 2004;25:793-801.

  18. Rozen S, Skaletsky HJ. Primer3 on the WWW for general users and for biologist programmers. In: Misener S, Krawetz SA (eds). Bioinformatics methods and protocols. Methods in Molecular Biology. Totowa: Humana Press; 2000.

  19. Vandesompele J, De Preter K, Pattyn F, Pope B, Van Roy N, De Paepe, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3(7):RESEARCH0034.

  20. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci. 2004;117(8):1281-3.

  21. Serasanambati M, Chilakapati SR. Function of nuclear factor kappa B (NF-kB) in human diseases-A Review. South Indian J Biol Sci. 2016;2(4);368-87.

  22. Ji H, Wang J, Nika H, Hawke D, Keezer S, Ge Q, et al. EGF-induced ERK activation promotes CK2-mediated disassociation of alpha-catenin from beta-catenin and transactivation of betacatenin. Mol Cell. 2009;36(4):547-59.

  23. Kindon H, Pothoulakis C, Thim L, Lynch- Devaney K, Podolsky DK. Trefoil peptide protection of intestinal epithelialbarrier function: cooperative interaction with mucin glycoprotein. Gastroenterology. 1995;109:516-23.

  24. Foersch S, Neurath MF. Colitis associated neoplasia: molecular basis and –3 –3 –4 –4 0 0 –1 –1 –2 –2 2 2 1 1 Gene expression change level Gene expression change level GFI1 KLF4 ELF3 CSNK2A1 CSNK2B BCAR1 MAPK1 EGFR MAPK10 EPS8 MAPK3 GAB1 MAPK8 GRB2 MAPK9 HRAS MKNK1 KRAS NCK2 RAP1A MAP2K1 NRAS RASA1 MAP2K4 RAF1 RHOA MAP2K7 MAP3K2 ** ** ** * * ** * ** * * ** * ** ** ** * ** ** ** * ** ** * * ** A B Figure 3. Changes of expression levels for proliferation and differentiation of intestinal cells genes detected by qPCR in colonic biopsies of rats with DSS-induced ulcerative colitis, treated with pellets of recombinant human epidermal growth factor (rhEGF). A) Wnt/β-Catenin pathway genes. B) Epidermal growth factor pathway genes. Values stand of the expression change levels of each gene for rhEGF-Pellet-treated animals with 250 or 500 μg/pellet/day compared to placebo-treated rats (white bars) or DSS-UC vs. healthy rats (black bars; data taken from Roca et al. Bionatura. 2018; 3(2):577-81). Statistically significant differences are indicated (* p < 0.05, ** p < 0.01). rhEGF treatment vs. placebo DSS-UC vs. healthy rats rhEGF EGF pathway Caliciform cell differentiation Formation of the protective Mucin barrier Proliferation of intestinal epithelial cells Wnt/β-Catenin pathway Up-regulation Down-regulation Restoration of the intestinal epithelial barrier Inflammation Oxidative Stress Signal transduction pathway CNK2B KLF4 BCAR1 HRAS RAFA1 MAPK1 MAPK3 Figure 4. Putative mechanism of action for the treatment of ulcerative colitis with recombinan human epidermal growth factor (rhEGF) in pellet formulations. Experimental results supporting the proposed model were obtained in the DSS-induced ulcerative colitis model in rats. clinical Translation. Cell Mol Life Sci. 2014;71: 3523-35.

  25. Shelton EH, Dawson LT, Li X, Yu H. Heterodimerization and functional interaction between EGF receptor family members: A new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat. 1995; 35:115-32.

  26. Garrido JB, Hernández-Calleros JI, García- Juárez I, Yamamoto-Furusho JK. Growth factors as treatment for inflammatory bowel disease: A concise review of the evidence toward their potential. Saudi J Gastroenterol. 2009; 15(3):208-12.

  27. Ferguson LR. Chronic inflammation and mutagenesis. Mutat Res. 2010;690:3-11.

  28. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004;118:285-96.

  29. Dube PE, Yan F, Punit S, Girish N, McElroy SJ, Washington MK, et al. Epidermal growth factor receptor inhibits colitisassociated cancer in mice. J Clin Invest. 2012;122(8):2780-92.

  30. Dube PE, Liu CY, Girish N, Washington MK, Polk DB. Pharmacological activation of epidermal growth factor receptor signaling inhibits colitis-associated cancer in mice. Sci Rep. 2018;8(1):9119.




2020     |     www.medigraphic.com